Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,801–13,900 of 15,747
Clinical Spectrum of COVID-19 Patients after Vaccination
Niaz, A., Younas, M. T., Nayyar, S., et al. (2022) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v72i6.7323
Rees, A. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43876-9.00007-7
Wang, K., Zeng, T., Guo, Z., Liang, J., Sun, S., Ni, Y., Yan, C., Yin, L., Wang, L., Li, H., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10250-1
Islam, M. N., Allegri, M. D., Bonnet, E., Sarker, M., Goudet, J.-M., Franceschin, L., & Ridde, V. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004178
“While it is true that vaccination against COVID-19 cannot solve all the challenges posed by the pandemic [3], it plays a vital role in reducing the risk of infection, transmission, hospitalization, and death [4].”
Synopsis on COVID19 Vaccine Development
Watt, B. (2021) · Caribbean Medical Journal · doi:10.48107/cmj.2021.03.008
mRNA Delivery by Lipoamino Fatty Acid–Peptide Polyplexes in Different Lung Cell Models and Lungs
Thalmayr, S., Müller, J. T., Polewka, V., Gialdini, I., Nguyen, A., Dohmen, C., Lamb, D. C., Merkel, O. M., & Wagner, E. (2026) · Polymers · doi:10.3390/polym18111368 · Cited by 1
Side Effects of COVID-19 Vaccination Among Medical Students in Bangladesh: A Cross-Sectional Study
Islam, A. S. M. S., Sanjana, S., Azad, S. U., Saify, S., Trisha, M. S., & Nahid, M. H. (2025) · Cureus · doi:10.7759/cureus.96937
“Clinical trial evidence for ChAdOx1, BNT162b2, and mRNA-1273 indicates that systemic reactogenicity can be more prominent following the second dose, yet adverse events remain transient and of mild-to-moderate intensity in the vast majority of cases [5-7].”
A Mathematical modeling approach to the long-term global impacts of COVID-19
Celestine, A. B., Ahman, Q. O., Emadifar, H., et al. (2026) · International Journal of Mathematics for Industry · doi:10.1142/s2661335226500085
Historical advancements in targeted nanoscale drug delivery systems
Singh, S., Kalia, P., Kumar, R., Pundir, S., Chaturvedi, V. K., Singh, A. K., Awasthi, R., Singh, S. K., & Singh, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24802-3.00020-2
Tratamento da asma: o que podemos aprender com um médico do século XVI
Melo, R. E. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200046
Cherchi, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-94841-1_147
Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccinePreprint
Carnell, G., Vendramelli, R., Whittaker, C., Holbrook, J. A., Parthasarathy, S., Stewart, H., Olivier, J., Warner, B. M., Truong, T., George, C. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.17.25338244
“Within two years, vaccines against SARS-CoV-2 greatly contributed to preventing severe COVID-19 disease and significantly reducing human fatalities 5 – 7 .”
Goncheva, M. I., Gibson, R. M., Shouldice, A. C., Dikeakos, J. D., & Heinrichs, D. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497883
Systematic Review and Meta‐Analysis of Emerging Viral Zoonotic Diseases, 2016–2026
Tao, P., Ying-an, Z., Wang, J., Cong, F., & Liao, M. (2026) · Transboundary and Emerging Diseases · doi:10.1155/tbed/9884191
What’s New in Musculoskeletal Basic Science
Bahney, C. S., Stoddart, M. J., Miclau, T., & Marcucio, R. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.01234
Nadal, E., Morán, T., Estival, A., Sala, M. Á., Antoñanzas, M., González, J. G., Diz-Taín, M. P., Martínez, M., Azcona, E., Baena, J., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100125
Introduction to a review series on RNA therapeutics in hematology
Gotlib, J. R. (2023) · Blood · doi:10.1182/blood.2023020910
da Silva, J. R. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-17032022-102622 · Cited by 1
INCIDÊNCIA DA COVID-19 NO RIO GRANDE DO NORTE E ESTRATÉGIAS DE CONTROLE DA PANDEMIA
Lucena, D. D. S., Nascimento, D. P. C. D., Leite, I. F., et al. (2024) · Revista de Ciências da Saúde Nova Esperança · doi:10.17695/rcsne.vol22.n2.p174-182
Functional comparison of SP6 RNA polymerase and T7 RNA polymerase
Gutbrod, J., Hehn, S., Bangnowski, A., Fritz, E., & Marx, A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351567
“Research has spiked, especially on the development of mRNA vaccines, which have proven to be a powerful tool against viral pathogens like SARS-CoV-2 [1,2].”
In vivo gene delivery to immune cellsPreprint
Siebart, J. C., Chan, C. S., Yao, X., Su, F., & Kwong, G. A. (2023) · doi:10.31219/osf.io/d26uf
Kobayashi, Y., Ishikawa, N., Tateishi, Y., Izumo, H., Eguchi, Y., Fujii, Y., Ono, H., & Okada, S. (2023) · Journal of Pediatric Epilepsy · doi:10.1055/s-0043-1770363
Roussel, C. (2021) · theses.fr (ABES) · doi:10.70675/f3a0270cz3894z4ff4za156z608bfa918d9e · Cited by 2
Investigation de l’épidémie de la rougeole 2017-2019 à Marseille, France
Jaafar, R. (2022) · theses.fr (ABES) · doi:10.70675/01ade9d1z58a3z410bzb1ccz08a5cdbbec26
Sellers, R. S., & Nelson, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00029-4
Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection
Wei, A., Miao, Y., Yuan, Z., Li, G., Lei, D., Ma, Y., Guo, Z., Sun, Y. W., Ding, T., Tian, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75413-x · Cited by 2
“Delivering mRNA-LNP vaccines directly to the lungs may offer unique advantages in combating respiratory infections, including localized immune activation, rapid innate response engagement, and mucosal protection 24 – 26 .”
Курмангалиева, С. С., Уразаева, С. Т., Жаксыбай, З. А., Бегалина, Н. А., Kurmangaliyev, K. B., & UREKESHOV, B. S. (2023) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2023.89.82.011
Gushchin, V. A., Siniavin, A. E., Pochtovyi, A. A., Dzharullaeva, A. S., Щербинин, Д. Н., Ungur, A. S., Ильдарович, Т. А., Shuliakova, I. V., Kleymenov, D. A., Mazunina, E. P., et al. (2026) · Vaccines · doi:10.3390/vaccines14030281
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1764 · Cited by 1
Bozok, T., GÜLBUDAK, H., Ülger, S. T., & Aslan, G. (2023) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20239904
Paynter, J., McIntyre, P., Wiki, J., Nghiem, N., Liu, B., Marek, L., & Hobbs, M. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100624
Development of a Quantitative ELISA Kit for Restriction Enzyme BsaiPreprint
Li, Z., Chen, L., Yang, M., Luo, Z., Xu, H., & Ren, H. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4699724
Malysheva, N., & von Kleist, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.22.469498
“…isolation or quarantine, may further reduce the transmission rate by reducing r e , whereas pharmaceutic (vaccination, prophylaxis, treatment) [42–44] or non-pharmaceutic interventions (e.g. mask wearing for airborne-, and condom usage for sexually transmitted infections) [45,46] may lower p…”
BackgroundImmunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
Thookhamme, C., Navinpipat, M., Sasakul, A., Pattarakosol, P., Lertchaisataporn, K., Tawinprai, K., & Praditsuktavorn, P. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.2.107
“107 particularly severe cases of the disease [3-6]; however, the diminished efficacy of SARS-CoV-2 vaccines in patients with hematologic cancer is a concern.”
BackgroundImmune Response to BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Healthcare Workers
Gómez, G. G., Martínez-Lacasa, X., Jaen, A., Martínez, J. V., Padilla, E., Clemente, D., Molina, S., Chlouba, A., Gonzalez, S., & Monzón-Camps, H. (2024) · Cureus · doi:10.7759/cureus.75188
Caring for Pregnant Patients by Including Pregnant Participants
Rizzuto, J., Pyne, A. S., & Gatta, L. A. (2024) · The Journal of Clinical Ethics · doi:10.1086/732214
Rasendran, C., Haueisen, A., Wadhwa, R., et al. (2021) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20210930-01
Emergency Medicine JournalCOVID-19 monthly top five
Tonkins, M., Miles, J., O'Keeffe, C. A., et al. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-211203
Pektas, A., Tunç, İ., Aslan, B., Akçalı, N., & Batur, L. K. (2026) · The European Chemistry and Biotechnology Journal · doi:10.62063/ecb-84
Le, T. V., Imai, S., Fujitsuka, I., Ueda, M., Nakamae, S., Mizukami, S., Hanayama, R., & Yamano, T. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2736339
陶剑, Zhao, J., Liu, Y., Hu, L., Zhou, H., Wang, B., & Kang, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10570513/v1
SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases
Furer, V. (2022) · touchREVIEWS in RMD · doi:10.17925/rmd.2022.1.2.38
Nakamura, N., Tsunemine, H., Ikunari, R., Sakai, T., & Arima, N. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2343519
Ricard, C. A., Poyant, J., Holewinski, S., & Nasraway, S. A. (2021) · Journal of Hospital Administration · doi:10.5430/jha.v10n2p29
“Predicted Hospital Mortality ACUITY2019, % 28 [5-58] (n = 103) 5 [2-15] (n = 200) 23 (10.”
Chaitanya, K., Mary Rohini, P., Bhuvaneshwari, G., et al. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i6.52569
“In the study by Polack et al., 15 it was observed that there was slight male predominance in the trial compared to female (50.6 vs. 49.4%).”
ResultInfluentialPulmonary mRNA-LNP Vaccines for Rapid and Durable Protection Against Bacterial InfectionPreprint
Wei, X., Wei, A., Yu, M., Yuan, Z., Li, G., Lei, D., Ma, Y., Guo, Z., Sun, Y., Ding, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695407
Sawatari, H., Omode, A., Kawada, H., Teramoto, C., & Tanabe, K. (2026) · Creative Nursing · doi:10.1177/10784535261459640 · Cited by 1
Wei, H., Lu, L., Xu, Y., Lü, X., Zhang, Y., Zhang, X., & Huang, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3674274/v1
Lee, J., Jo, H., Cho, H., Oh, J., Jeong, Y. D., Lee, S., Park, J., Kim, H. J., Son, Y., Kim, S., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70408
“S [15] (Janssen/Johnson & Johnson; vaccine group n = 21 895), mRNA ‐ 1273 [16] (Moderna; vaccine group n = 15 181), and BNT162b2 [17] (Pfizer/ BioNTech; vaccine group n = 18 860) vaccines reported no diagnosed cases of TM.”
Understanding the cellular pathogenesis of COVID-19 symptoms using organoid technology
Che, Y. H., & Kim, Y. J. (2022) · Organoid · doi:10.51335/organoid.2022.2.e16
Löfström, E., Eringfält, A., Kötz, A., Tham, J., & Undén, J. (2024) · Apmis · doi:10.1111/apm.13489 · Cited by 1
Chen, S.-H., Ho, Y., Lin, S.-J., & Liu, H. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2648674
Le, D., & Wert, Y. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08371-w
Bitler, J. (2022) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v25i3.7016
Carlini, V., Trabucchi, E., Santo, N., Lattuada, N., Saccucci, S., Allevi, R., Rispoli, F., Bianchi, B., Longhi, E., Macas-Granizo, M. B., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119961
Rocha, A., Milan, E. P., Caminha, R. O. D. C., et al. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.613_port
Lombardi, F., Belmonti, S., & Giambendetto, S. D. (2023) · PubMed · doi:10.53854/liim-3103-9
Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID ‐19 Pandemic
Sällberg, M. (2026) · Acta Paediatrica · doi:10.1111/apa.70762 · Cited by 1
Wang, L. Q., & Smith, L. W. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/fnahoszh2z
Assessing the Impact of Vaccination Strategies on COVID-19 Dynamics Via Time-varying Copulas
Ahdika, A., Fakhruddin, M., & Swastika, P. V. (2026) · Acta Biotheoretica · doi:10.1007/s10441-026-09523-w
COVID-19 vaccines: A comprehensive review of safety and efficacy
Yan, Z., Yang, M., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00028-0
Update zu: SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
Salzberger, B., Buder, F., Lampl, B. M. J., Ehrenstein, B. P., Hitzenbichler, F., Bauernfeind, S., Holzmann, T., Schmidt, B., & Hanses, F. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00529-8
“Bis Ende des Jahres 2020 wurden in Europa und den USA 3 Impfstoffe aufgrund der Daten zur Wirksamkeit und Sicherheit zugelassen und breit eingeführt [4, 10].”
BackgroundOliva‐Ariza, G., Criado, I., Fuentes‐Herrero, B., Carbonell, C., Sánchez-Gallego, J. I., López‐Bernús, A., Gutiérrez, M. L., Rolo-Ramírez, A., Bernal‐Ribes, M., Almenara-Morales, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020681 · Cited by 1
Madni, A. U. H., Hassan, N., Hameed, S. M., Satti, M. N., Ullah, R. H., Adnan, H., Mushtaq, M. F., & Faridi, T. A. (2025) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v8i8.1299
Adverse Events Related to SARS-Cov-2 Vaccination: A Systematic Review and Meta-Analysis
Bello, S., Ajayi, D. T., Adepoju, A., Omotosho, T., Afolabi, R. F., Gbadebo, B. M., Salawu, M. M., Bamgboye, E. A., Oduwole, O. A., Fagbamigbe, A. F., et al. (2023) · Journal of Epidemiology and Public Health · doi:10.26911/jepublichealth.2023.08.03.01
Understanding the molecular basis of pathogenesis of SARS-CoV-2
Parveen, M., Badar, M. S., Khan, Y. T., Nehal, A., & Jilani, L. Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95374-0.00014-2
Wahono, C. S., Rahman, P. A., Parlindungan, F., KW, R. S. A., Ariane, A., Yani, H., Ginting, A. R., Sari, L. K., Kurniari, P. K., Manuaba, R., et al. (2021) · Indonesian Journal of Rheumatology · doi:10.37275/ijr.v13i1.167
Dos and Don’ts in der rheumatologischen Primärversorgung
Thonhofer, R. (2024) · rheuma plus · doi:10.1007/s12688-023-00698-5
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
“The authorization and global deployment of COVID-19 messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 demonstrated that synthetic mRNA can be manufactured rapidly, protected from extracellular nucleases and translated in vivo with clinically meaningful potency [1–5].”
Ventura, A. (2021) · Medico e Bambino · doi:10.53126/meb40557
Maternal Mortality During the COVID-19 Pandemic in Tamaulipas, Mexico: A Retrospective Study
Martínez-Padrón, H. Y., Quintero-Zapata, A. G., Buenfild-Saldivar, A. D., et al. (2025) · COVID · doi:10.3390/covid5120200
“Leik et al. (2021) and Polack et al. (2020) concluded in their article that the vaccine against SARS-CoV-2 offers protection against the virus and does not represent a risk for the patient or the fetus [33,34].”
Mataix, R. P., Morillo, J. S. G., & Martín, J. M. S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.12.007
Sehgal, S. A., Malik, G., Atri, R., et al. (2023) · Journal of Research in Applied and Basic Medical Sciences · doi:10.61186/rabms.9.4.200
Analysis of adverse effects caused by mRNA vaccines used in the fight against COVID-19
Pitoscia, G. O., & Faria, T. V. (2021) · MedNEXT Journal of Medical and Health Sciences · doi:10.54448/mdnt21602
“The incidence of myocarditis after vaccination was 50 cases per million for men aged 18 to 30 years [16].”
BackgroundDhayfule, D., Wu, Y.-H., Ashyani, A., Li, M.-C., Tsai, C.-S., Chen, P., & Nordling, T. E. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11289-4
“The BNT162b2 vaccine trial had the most participants (21720 in the vaccine and 21728 in the placebo groups) of any phase III clinical trial [19].”
Hayashi, T., Sano, K., & Konishi, I. (2024) · medRxiv · doi:10.1101/2024.03.18.24304517
Hesitancy towards COVID-19 Vaccination and Neutralization of False Perceptions among the Communities
Weerawarna, P. S. H., Habib, M., & Abbas, M. (2021) · Pakistan Journal of Public Health · doi:10.32413/pjph.v11i2.780
“However, the high cost and requirement of freezing temperatures to be stored has caused this to be an unpopular option in low- and middle-income countries (12).”
BackgroundA Survey for Pharmacist Opinions on the Promoting of Public Uptake of the COVID-19 Vaccination
Yoshizawa, T., Azechi, T., Fukuhara, N., Saito, T., Sasano, H., & Arakawa, R. (2021) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.47.701
Modeling-based strategies for ICU-bed management during the COVID-19 pandemic
Jang, G., Park, S., Choi, Y., Choi, S. J., & Lee, H. (2026) · Advances in Continuous and Discrete Models · doi:10.1186/s13662-026-04055-6
Bölgemizde Uygulanan Biontech ve Sinovac Aşılarına Karşı Gelişen Antikor Yanıtının Değerlendirilmesi
Çeylan, K., Karslığil, T., Aşkın, F. N., & Özen, G. K. (2023) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1088761
Advances in Computational Approaches for Biopharmaceutical Formulation
Lai, P. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_4
Estrategia vacunal en las virasis hibernales: presente y futuro
Moreno-Millán, N., Iglesias, J. B., & Raya, P. R. (2023) · Atención Primaria · doi:10.1016/j.aprim.2023.102674
Psychosocial Factors Influencing Vaccine Hesitancy: A Study in the Context of COVID-19Preprint
Rahel (2024) · Research Square · doi:10.21203/rs.3.rs-4156314/v1
Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) VaccinePreprint
Yechezkel, M., Mofaz, M., Patalon, T., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4145588
Randomization, blinding, and multicentric considerations in clinical trials
Sachdeva, S., & Lobbous, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90509-1.00012-6
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0012
Djordjević, N., Matić, S. L., Milovanovic, D. R., Stefanović, S., Popović, S., Todorović, D., Djurdjevic, P. M., Sazdanovic, P. S., Antic, V., Lončar, S., et al. (2024) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh221215037d
(2021) · Actualité et dossier en santé publique · doi:10.3917/aedesp.116.0066 · Cited by 1
Knowledge and attitudes about vaccinations between healthcare providers and the general population
Ruby, D. (2025) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ecdt.ecdt_101_24
Kelly, J. D., Leonard, S. J., Boscardin, W. J., Hoggatt, K. J., Lum, E. N., Austin, C., Byers, A. L., Tien, P. C., Bravata, D. M., & Keyhani, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-61244-7 · Cited by 1
Achievements of the last biennium, projections for the coming years, and the impact of COVID-19
Baldi, B. G., & Godoy, I. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210001
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.